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years—from the statutory health insurance (SHI), family and societal perspec-
tives— the number of AD cases, the direct medical, non-medical, and productivity
loss costs, and quality adjusted life-year (QALY) in infant receiving each formula
type for 4 months. The model included the following health states: disease free,
mild, moderate, and severe AD, and death. Efficacy estimates were based on the
German Infant Nutritional Intervention trial. Outcomes were discounted at 3% and
reported as cost per QALY gained and per avoided cases of AD. Extensive deter-
ministic and probabilistic sensitivity analyses (SA) were performed. RESULTS: In
the base case, pHF-W resulted in 0.016 (95% CI: 0.0066; 0.0249) QALY gained and 0.14
AD cases avoided per patients relative to SF, with corresponding estimated incre-
mental saving (SHI perspective) of €70.14 (95%CI: €16.26; €145.94;) per patient.
pHF-W resulted in 0.006 (95% CI: 0.0004; 0.0149) QALY gained and 0.04 AD cases
avoided per patients relative to eHF-W, with corresponding estimated incremental
saving (SHI perspective) of €424 (95%CI: €106.94; €848.26) per patient. Univariate SA
revealed that incremental QALYS and costs were most sensitive to changes in the
relative risk of developing AD up to one year when PHF is compared to SF and
reimbursement rates of formula for prevention. CONCLUSIONS: AD prevention
with pHF-W is a cost-effective strategy compared to SF and eHF-W.
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OBJECTIVES:Allergic rhinitis due to ragweed pollen is characterized by rhinorrhea,
itching, and nasal congestion. Methods of ragweed control, such as cutting and
mowing, are important to reduce the atmospheric concentration of pollen, thus
reducing the severity of AR symptoms and improving patients’ quality of life. The
aim of this study was to assess the economic impact of an intensive concerted
intervention mode (CIM) compared to a minimal intervention mode (MIM) in a
Quebec provincial context. METHODS: A cost-utility analysis was performed ac-
cording to a societal perspective. A time horizon of one month was chosen, which
correspond to the symptomatic period of AR due to ragweed pollen. CIM and MIM
were applied in two comparable cities from Quebec. The target population was
composed of people living in both cities, with a focus on patients suffering from AR
related to ragweed pollen. Clinical data were obtained from the Rhinoconjunctivitis
Quality of Life Questionnaire (RQLQ) and were converted into utility values using
the method proposed by Keiding and Jorgenson. Costs considered in this economic
evaluation were those necessary for the mobilization and sensitization of commu-
nity sectors, equipment, and additional typical methods of ragweed control.
RESULTS: RQLQ scores were obtained from 227 patients (106 for CIM and 121 for
MIM). For the population where the CIM was adopted, total cost of interventions
was CDN$60,603 and a gain of 10.15 QALYs was estimated. In the city with the MIM,
there were no additional costs and a decrease of 0.40 QALY was observed. The
incremental cost-utility ratio was estimated at CDN$5744/QALY. CONCLUSIONS:
This economic evaluation demonstrates that a CIM is a cost-effective strategy
compared to a MIM. Results of this study support the adoption of intensive inter-
vention programs in the control of AR due to ragweed pollen.
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OBJECTIVES: To assess the effect of subcutaneous-allergen-specific-immunother-
apy (SCIT) on disease severity classifications, number of days affected and sick
days per year on patients with grass-pollen and/or house dust mite (HDM) induced
allergic rhino-conjunctivitis (RC) and/or asthma (A). METHODS: A total of 248 pa-
tients started SCIT; an intension to treat approach was applied. The disease specific
Rhino-conjunctivitis Quality of Life Questionnaire (RQLQ) and the two generic
health-related quality of life (HRQoL) instruments 15D and EQ-5D were used. The
outcome measures included change in; disease severity classifications, RQLQ-
scores, number of days with symptoms, number of sick days, change in generic
HRQoL and Quality-Adjusted-Life-Years (QALY). RESULTS: The disease severity
classifications showed significantly improved disease control. Mean RQLQ-score
was reduced from 3.02 at baseline to 2.00 at follow-up. Average annual days with
symptoms were reduced from 189 days to 145 days whilst annual sick days were
reduced from 3.7 to 1.2 days. The 15D-score increased from 0.83 to 0.86 and the
EQ-5D-score from 0.70 to 0.77, which indicated an annual gain per patient of 0.03-
0.06 QALY. CONCLUSIONS: Allergic patients suffering from RC alone or RC and A
experience significantly increased HRQoL, when treated with SCIT for one year.
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OBJECTIVES: To examine correlates of non-adherence to drug therapy among
COPD patients in 5EU. METHODS: The study included data from the 2011 5EU
(N57,512) National Health and Wellness Survey, a survey representative of the
adult populations in France, Germany, Italy, Spain, and UK. Patients self-reported
physician diagnosis of COPD, chronic bronchitis, or emphysema and indicated they
were currently taking a prescription regimen for their condition. Adherence was
measured using the Morisky Adherence Scale. T-tests and chi-square tests were
used to assess differences between adherent and non-adherent patients. A binary
logistic regression model was used to determine patient characteristics indepen-
dently associated with non-adherence. Sex, age, smoking, alcohol use, Charlson
Comorbidity Index (CCI), out of pocket costs for prescriptions, use of cost saving
strategies (CSS), self-reported COPD severity, employment, income, number of co-
morbid conditions, and country were included as predictors. RESULTS: Of 1,263
respondents using a COPD medication, 30% (n375) reported at least one non-
adherent behavior. Bivariate comparisons revealed that non-adherent patients
were more likely to smoke and use CSS than adherent patients (49% vs. 36% and
48% vs. 32%, respectively; ps0.001). Adherent patients were also older (57.9 vs.
52.3) and experienced more severe COPD (17% vs. 9%; ps0.001). In the regression
model, age (OR: 1.02, 95% CI: 1.01, 1.03) and severe COPD (OR: 1.90, 95% CI: 1.21, 2.99)
were positively associated with adherence (ps0.01), while smoking (OR: 0.66, 95%
CI: 0.51, 0.86) and use of CSS (OR: 0.61, 95% CI: 0.46, 0.81) had negative associations
(ps0.01). No other variables in the model were associated with adherence.
CONCLUSIONS: In 5EU, advanced age and severe COPD are associated with in-
creased adherence, while smoking and CSS with are associated with decreased
adherence. Physicians need to target their younger, less severe COPD patients to
encourage greater adherence to therapy.
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OBJECTIVES: To assess the impact of the community pharmacy Spiriva New To
Therapy (SNTT) compliance program on adherence and persistence. METHODS:
Patients presenting at participating community pharmacies with their first script
for tiotropium were invited to participate in a pharmacist intervention involving
two 10 minute protocol based coaching sessions, one month apart. Records were
extracted of tiotropium scripts dispensed for all patients enrolled in the SNTT
program over the following 12 months. Adherence was assessed by MPR over the
first 6 months. Patients were considered to have ceased tiotropium if there was a
three month gap in dispensed scripts. Time to cessation of tiotropium treatment
was assessed using the Kaplan-Meier method. The SNTT program was compared
with persistence curves derived from a 10% random sample of tiotropium patients
using the Australian prescription claims database (SPBS). RESULTS: A total of 246
patients enrolled in the SNNT program; 48% completed Session #1, while 52% com-
pleted both Sessions. Over the first 6 months, SNTT program patients collected 5.2
tiotropium scripts indicating satisfactory adherence (MPR  87% vs 55%); 2% of
SNTT patients ceased tiotropium after the first prescription (SPBS37%), while just
38% (63%) had stopped after 10 months. Persistence by patients completing two
sessions was slightly better than those completing one. CONCLUSIONS: A phar-
macist intervention involving two short protocol based coaching sessions signifi-
cantly reduced the early cessation of tiotropium. A total of 35% to 40% more SNTT
program patients were persistent than the Australian SPBS population at 3-6
months. MPR was significantly improved.
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OBJECTIVES: Hereditary angioedema due to C1 inhibitor deficiency (HAE) is a rare
but serious disease marked by swelling attacks in various areas of the body. The
HAE Burden of Illness Study-Europe (HAE-BOIS-Europe) addresses the gaps in our
knowledge of the humanistic and economic impact of HAE in Europe. We report the
economic results. METHODS: This cross-sectional study was conducted in Spain
(ES), Denmark (DK), and Germany (DE), and was open to patients aged 12 years,
with a diagnosis of HAE-I or HAE-II. Data collection included a survey on individu-
als’ direct and indirect resource utilization, and the impact of HAE on work, school
and other activities. RESULTS: A total of 186 patients participated. From 84-100%
across countries reported having medication at home to treat attacks, although
48%, 25%, and 23% in ES, DK, and DE, respectively, still received care at a treatment
facility or saw a physician for their most recent attack; 21%, 18%, and 0%, respec-
tively, visited an emergency department. On a 0.0-10.0 (higher worse) rating scale
of the impact of the attack on ability to perform daily activities, patients reported a
mean score of 5.0; this did not vary significantly by site of attack. Overall, 24% of
patients missed time from work/school during the most recent attack, missing a
mean of 2.9 days, and 29% missed time from work/school between attacks over the
past 6 months, missing a median of 2.0 days. Overall, 59% required carer help over
the past 6 months, with a corresponding detriment to the carers’ work and/or
leisure time. Overall, 48% of patients reported that HAE has hindered their career
and/or educational advancement. CONCLUSIONS: The HAE-BOIS-Europe survey
has highlighted the substantial economic burden of HAE, which encompasses
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